PapersFlow Research Brief
Endometrial and Cervical Cancer Treatments
Research Guide
What is Endometrial and Cervical Cancer Treatments?
Endometrial and cervical cancer treatments encompass surgical, radiotherapeutic, chemotherapeutic, and molecular-targeted approaches to manage endometrial carcinoma and cervical cancer, including techniques such as brachytherapy, sentinel lymph node biopsy, chemoradiotherapy, and robotic surgery.
Research on endometrial and cervical cancer treatments covers molecular classification, radiation therapy including brachytherapy, sentinel lymph node biopsy, chemoradiotherapy efficacy, robotic surgery advancements, and survival analysis, with 78,703 works in the field. Rose et al. (1999) in "Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer" demonstrated that cisplatin-based regimens with radiotherapy improve survival and progression-free survival rates in women with locally advanced cervical cancer. Bokhman (1983) in "Two pathogenetic types of endometrial carcinoma" identified distinct pathogenetic types of endometrial carcinoma influencing treatment strategies.
Topic Hierarchy
Why It Matters
Treatments for endometrial and cervical cancer directly impact survival outcomes in gynecologic oncology. Rose et al. (1999) showed in "Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer" that combining cisplatin-based chemotherapy with radiotherapy improves survival rates compared to radiotherapy alone in locally advanced cases. Sentinel lymph node biopsy and robotic surgery enhance precision in staging and resection, reducing morbidity while maintaining efficacy in endometrial carcinoma management. Chemoradiotherapy protocols, as evidenced by high-citation works, guide clinical practice guidelines for managing these cancers worldwide.
Reading Guide
Where to Start
"Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer" by Rose et al. (1999), as it provides foundational evidence on a standard treatment improving survival rates, making it accessible for understanding chemoradiotherapy principles.
Key Papers Explained
Rose et al. (1999) in "Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer" established cisplatin-radiotherapy as a survival-improving standard for cervical cancer, cited 2625 times. Bokhman (1983) in "Two pathogenetic types of endometrial carcinoma" (2462 citations) classified endometrial types, informing targeted therapies. Bosch et al. (2002) in "The causal relation between human papillomavirus and cervical cancer" (3534 citations) confirmed HPV causality, linking etiology to prevention-integrated treatments. Pecorelli (2009) in "Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium" (2843 citations) updated staging to align with these advances.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research focuses on molecular classification and survival analysis from clinical practice guidelines, with emphasis on brachytherapy refinements and robotic surgery integration. No recent preprints or news available indicate steady application of established protocols like chemoradiotherapy.
Papers at a Glance
Frequently Asked Questions
What is the role of cisplatin-based chemoradiotherapy in cervical cancer?
Rose et al. (1999) in "Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer" found that regimens combining radiotherapy and cisplatin-based chemotherapy improve survival and progression-free survival rates in women with locally advanced cervical cancer. This approach outperforms radiotherapy alone. It serves as a standard for stage IB2 to IVA disease.
How do pathogenetic types affect endometrial carcinoma treatment?
Bokhman (1983) in "Two pathogenetic types of endometrial carcinoma" described two distinct types with different etiologies and prognoses, influencing surgical and adjuvant therapy choices. Type I tumors are estrogen-dependent with better prognosis, often treated with hysterectomy. Type II tumors are more aggressive, requiring more intensive multimodal therapy.
What is the causal link between HPV and cervical cancer?
Bosch et al. (2002) in "The causal relation between human papillomavirus and cervical cancer" established that HPV infections cause virtually all cervical cancer cases worldwide. This supports HPV-based prevention and screening in treatment paradigms. Medical societies now recognize this for public health guidelines.
What staging system is used for endometrial and cervical cancer?
Pecorelli (2009) in "Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium" updated the FIGO staging to reflect prognostic factors and guide treatment decisions. It incorporates lymph node status and tumor invasion depth. This revision standardizes global management.
How prevalent is HPV in cervical cancer globally?
Bosch et al. (1995) in "Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective" showed over 20 genital HPV types associated with cervical cancer across regions. This informs vaccine development targeting high-risk types. Prevalence data supports universal HPV vaccination strategies.
What are key techniques in endometrial cancer surgery?
Clinical research emphasizes sentinel lymph node biopsy and robotic surgery for endometrial carcinoma to improve staging accuracy and reduce complications. These methods are part of practice guidelines. Survival analysis validates their outcomes.
Open Research Questions
- ? How can molecular classification refine treatment selection for the two pathogenetic types of endometrial carcinoma?
- ? What optimizations to cisplatin-based chemoradiotherapy can further improve progression-free survival in advanced cervical cancer?
- ? How does HPV genotype distribution influence personalized prevention and treatment strategies for cervical cancer?
- ? What survival benefits arise from integrating sentinel lymph node biopsy with robotic surgery in early-stage endometrial cancer?
- ? How do revised FIGO staging criteria impact adjuvant therapy decisions for high-risk endometrial and cervical cancers?
Recent Trends
The field maintains 78,703 works without specified 5-year growth data, reflecting sustained focus on established treatments like chemoradiotherapy from Rose et al.
1999High-citation papers from 1995-2010, such as Arbyn et al. on cervical cancer incidence (3911 citations), underscore ongoing global epidemiology integration into treatment planning.
2019No recent preprints or news signal stable reliance on validated techniques including sentinel lymph node biopsy.
Research Endometrial and Cervical Cancer Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Endometrial and Cervical Cancer Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers